Financial Results for the First Quarter of Fiscal Year Ending March 31, 2025
August 9, 2024
Stock Exchange Listings : Tokyo Stock Exchange

Company nameSecurities code
RepresentativeInquiries
TEL
Supplemental material of quarterly results
Convening briefing of quarterly results: JMS Co., Ltd.
(URL https://www.jms.cc/english/): 7702: Ryuji Katsura, President and Representative Director: Jo Sueda, Executive Officer, Head of Corporate Affairs Division: +81-82-243-5844: Yes
Dividend payable date (as planned): －: None(Note: Amounts below are rounded down to the nearest million yen)

1. Consolidated Financial Highlights for the Interim Period Ended June 2024 (From April 1, 2024 to June 30, 2024)(1) Consolidated operating results(%: change from the same previous period)
Profit attributable toNet sales
Operating profit
Ordinary profit
owners of parent
Millions of yen% Millions of yen% Millions of yen% Millions of yen%
Three months ended June 30, 2024
16,177 10.8
42 －
194 －(92) －Three months ended June 30, 2023
14,6002.2(111) －(73) －(260) －(Note) Comprehensive income : Three months ended June 30, 2024 : 1,200 million yen 〔4.1%〕,
Three months ended June 30, 2023 : 1,153 million yen 〔(24.5)%〕.

Three months ended June 30, 2024
Three months ended June 30, 2023

Basic earnings per share
Yen(3.77)(10.66)

Diluted earnings per share
Yen－－(2) Consolidated financial positions
Total assets
Net assets
Capital adequacy ratio
Millions of yen Millions of yen%
As at June 30, 2024
83,592
41,74449.7
As at March 31, 2024
84,70940,74747.9(Note) Owner's equity: June 30, 2024: 41,561 million yen, March 31, 2024: 40,573 million yen.
2. Dividends
1st quarter
Yen

Dividend per share
2nd quarter 3rd quarter Fiscal Year end
Yen
Yen
Yen
8.50
－
8.50

AnnualYen
17.00

8.50

17.00

Year ended March 31, 2024－
Year ending March 31, 2025－
Year ending March 31, 2025 (forecast)
8.50－(Note) Correction of dividend forecast from the most recent dividend forecast: None

3. Consolidated Forecast for the Year Ending March 2025 (From April 1, 2024 to March 31, 2025)(%: change from the same previous period)
Profit attributable to Basic earningsNet sales
Operating profit
Ordinary profit
owners of parent
per share
Millions of yen % Millions of yen % Millions of yen % Millions of yen %YenHalf year ending September 30, 2024
34,000 8.8
250
－250－
100－
4.08
Year ending March 31, 2025
70,000 7.2
800－
800 448.0
400
－
16.34
(Note) Correction of financial forecast from the most recent financial forecast. : None
The aforementioned projections are based on the information currently available, and may contain some uncertainties.
The final results might be significantly different from the aforementioned projections due to changes in business conditions.

Page 1 of 7

JMS (7702) Financial Results for the first Quarter of Fiscal Year Ending March 31, 2025

4. Overview of business result for the first quarter(1) Overview of consolidated business results
JMS strives to improve the quality of corporate management and the corporate value, in order ' To be a bridge
for the people who give and seek medical care, and to bring a smile to people by contributing to a healthy andbetter life' under our Founding Spirit of 'For People’s Precious Life'. JMS focused on four fields of businessactivities such as Infusion & Enteral Nutrition, Dialysis, Cardiovascular and Blood Management & Cell
Therapy and promotes product development, production and sales.
During the consolidated cumulative first quarter, sales of Closed Drug Mixing/Infusion Systems remainedstrong. Additionally, sales in Japan of Prefilled Syringes and Dysphagia-related products increased due to thedrug price revisions and the revision of medical service fees. In overseas markets, in addition to the mainstay
Apheresis Kits and Blood Bags, sales of Leukocyte Reduction Filters, a business acquired in the previous fiscalyear, increased.
As a result of the above, net sales of 16,177 million yen, up by 10.8% / 1,576 million yen (year-over-year), due
in part to the increase in yen-denominated sales resulting from the depreciation of the yen. Despite the effect ofsales increase, the growth of main products and the price increase from the previous year, Operating profit was
42 million yen (operating loss of 111 million yen in the same period of the previous year) due to the effect ofincreased sales, despite soaring raw material costs and increased manufacturing expenses. Ordinary profit
amounted to 194 million yen (ordinary loss of 73 million yen in the same period of the previous year) due toequity in earnings of affiliates and foreign exchange gains, and after income taxes, net loss attributable to ownersof the parent amounted to 92 million yen (net loss attributable to owners of the parent of 260 million yen in thesame period of the previous year).
Business performance by geographical segment.
(i) Japan
Despite a decrease in sales of medical gloves, sales of Prefilled Syringes, Dysphagia-related products, andClosed Drug Mixing/Infusion Systems were strong, and sales related to the Hemodialysis Business for Chinaincreased, resulted in net sales of 10,705 million yen (up 8.3% year-over-year). Segment profit of 252 million
yen (loss of 64 million yen in the same period of the previous year) due to the effect of increased revenue.
(ii) Singapore
In addition to increased sales of Apheresis Kits for North America and Blood Bags for Asia and Africa, theweaker yen also contributed to an increase in yen-denominated sales, resulted in net sales of 5,738 million yen(up 14.1% year-over-year). Segment profit of 40 million yen (loss of 59 million yen in the same period of theprevious year), despite the positive effect of increased revenue, due to factors such as the sharp rise in raw
material costs and increased labor costs.
(iii) China
Sales of AV Fistula Needles, Hemodialysis Blood Tubing Sets, and Hemodialysis Machines were strong,reflecting continued growth in demand due to market expansion, and net sales of 1,010 million yen (up 4.2%year-over-year) were recorded. Segment loss of 36 million yen (loss of 4 million yen in the same period of theprevious year) due to an increase in depreciation expenses associated with capital investment.
(iv) Philippines
Sales of Blood Bags for Asia and AV Fistula Needles for Europe declined, but sales of Infusion Sets andApheresis Kits for Japan increased, resulting in net sales of 911 million yen (up 1.3% year-over-year). Segment
loss of 149 million yen (segment profit of 14 million yen in the same period of the previous year) due to anincrease in labor and manufacturing expenses, despite increased sales.
(v) Germany
Sales of AV Fistula Needles and Blood Bags for Europe declined, resulting in net sales of 938 million yen (down11.4% year-over-year). Segment profit of 74 million yen (down 43.9% year-over-year) due to the impact oflower sales.

Page 2 of 7

JMS (7702) Financial Results for the first Quarter of Fiscal Year Ending March 31, 2025(vi) Others
Sales of Leukocyte Reduction Filters for China increased, resulting in net sales of 1,152 million yen (up 13.3%year-over-year) and a segment loss of 12 million yen (profit of 10 million yen in the same period of the previousyear).
(2) Overview of the financial condition
Total assets at the end of the first quarter of the current fiscal year decreased 1,116 million yen from the end of
the previous fiscal year to 83,592 million yen. Details of assets, liabilities and net assets are as follows.
(Assets)
Current assets decreased 1,918 million yen to 46,746 million yen. This was mainly due to a decrease in cash
and deposits resulting from repayment of loans payable. Fixed assets increased by 802 million yen from the endof the previous fiscal year to 36,845 million yen. This was mainly due to an increase in property, plant andequipment.
(Liabilities)
Current liabilities decreased 2,182 million yen to 27,747 million yen. This was mainly due to decreases in shortterm loans payable and current portion of long-term loans payable. Non-current liabilities increased 68 million
yen from the end of the previous fiscal year to 14,100 million yen. This was mainly due to an increase in leaseobligations.
(Net assets)
Net assets increased 996 million yen from the end of the previous fiscal year to 41,744 million yen. This was
mainly due to changes in foreign currency translation adjustments. The equity ratio increased 1.8 percentage
points from the end of the previous fiscal year to 49.7%.
(3)Overview of consolidated business forecast
Consolidated business forecast for the first half and ending of March 31, 2025 released on May 14, 2024 has
not been revised, as the overall business environment remained unclear.

Page 3 of 7

JMS (7702) Financial Results for the first Quarter of Fiscal Year Ending March 31, 2025

5. Consolidated Financial Statements

Consolidated Balance SheetJMS CO., LTD. and Consolidated Subsidiaries(Millions of yen)
As at March 31,2024
AssetsCurrent assets
Cash and deposits
Notes and accounts receivable - trade
Merchandise and finished goods
Work in process
Raw materials and supplies
Other
Allowance for doubtful accounts
Total current assets
Non-current assets
Property, plant and equipment
Buildings and structures, net
Machinery, equipment and vehicles, net
Other, net
Total property, plant and equipment
Intangible assets
Goodwill
Other
Total intangible assetsInvestments and other assets
Investments and other assets
Allowance for doubtful accounts
Total investments and other assets
Total non-current assets
Total assets

Page 4 of 7

As at June 30,
2024

10,30818,298
9,747
3,404
5,974
961
(30)
48,665

6,358
18,647
10,851
3,732
6,228
935
(7)
46,746

10,2539,304
9,521
29,07910,3609,427
10,13429,921

315
679
995

315
661
977

6,081
(112)
5,968
36,04384,709

6,037
(90)
5,947
36,84583,592JMS (7702) Financial Results for the first Quarter of Fiscal Year Ending March 31, 2025

Consolidated Balance SheetJMS CO., LTD. and Consolidated Subsidiaries(Millions of yen)
As at March 31,2024
Liabilities
Current liabilities
Notes and accounts payable - trade
Short-term borrowings
Current portion of long-term borrowings
Income taxes payable
Provision for bonuses
Other
Total current liabilities

As at June 30,2024

8,774
6,396
7,966
297
1,039
5,454
29,929

9,056
5,574
5,873
75
650
6,515
27,747

11,067
167
562
323
1,910
14,031
43,961

10,912
173
617
342
2,055
14,10041,847

Net assets
Shareholders' equity
Share capital
Capital surplus
Retained earnings
Treasury shares
Total shareholders' equity

7,411
10,351
17,055(194)
34,623

7,411
10,351
16,755(194)
34,323

Accumulated other comprehensive income
Valuation difference on available-for-sale securities
Foreign currency translation adjustment
Total accumulated other comprehensive income
Non-controlling interests
Total net assets
Total liabilities and net assets

779
5,169
5,949
174
40,74784,709

871
6,366
7,238
183
41,744
83,592

Non-current liabilities
Long-term borrowingsProvision for retirement benefits for directors (and other officers)
Retirement benefit liability
Asset retirement obligations
OtherTotal non-current liabilities
Total liabilities

Page 5 of 7

JMS (7702) Financial Results for the first Quarter of Fiscal Year Ending March 31, 2025

Consolidated statements of income
JMS CO., LTD. and Consolidated Subsidiaries(Millions of yen)Three months ended
June 30, 2023
Net sales
Cost of sales
Gross profit
Selling, general and administrative expenses
Operating profit (loss)

Three months ended
June 30, 2024

14,600
11,222
3,3783,489(111)16,177
12,541
3,635
3,592
42

Non-operating income
Interest income
Dividend income
Share of profit of entities accounted for using equity method
Foreign exchange gains
Other
Total non-operating income

225―
4135
104

3
31
102
79
25
242

Non-operating expenses
Interest expenses
Share of loss of entities accounted for using equity method
Other
Total non-operating expenses
Ordinary profit (loss)

4318366(73)

79―
1291
194

00000
45(77)
86
99
185(263)
(2)
(260)

―
55189
28
248
277(87)4(92)Extraordinary income
Gain on sale of non-current assets
Total extraordinary income
Extraordinary losses
Loss on sale of non-current assets
Loss on abandonment of non-current assets
Total extraordinary losses
Profit (loss) before income taxes
Income taxes - current
Income taxes - deferred
Total income taxes
Loss
Profit (loss) attributable to non-controlling interests
Loss attributable to owners of parent

Page 6 of 7

JMS (7702) Financial Results for the first Quarter of Fiscal Year Ending March 31, 2025

Consolidated statements of comprehensive income
JMS CO., LTD. and Consolidated Subsidiaries(Millions of yen)Three months ended
June 30, 2023

Three months ended
June 30, 2024

Loss
Other comprehensive income
Valuation difference on available-for-sale securities
Foreign currency translation adjustment
Total other comprehensive income
Comprehensive income

(263)

(87)

130
1,286
1,416
1,153

91
1,196
1,288
1,200

Comprehensive income attributable toComprehensive income attributable to owners of parent
Comprehensive income attributable to non-controlling interests

1,146
61,191
9Page 7 of 7